These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26277195)

  • 1. The α- and β-Adrenergic Antagonist Controversy with Sympathomimetic Agents.
    Banks ML; Worst TJ; Rusyniak DE; Sprague JE
    J Emerg Med; 2015 Dec; 49(6):e209-10. PubMed ID: 26277195
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-blocker use for toxicity from "bath salts".
    Richards JR; Laurin EG; Albertson TE
    J Emerg Med; 2015 Feb; 48(2):e45-6. PubMed ID: 25453853
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthetic cathinones ("bath salts").
    Banks ML; Worst TJ; Rusyniak DE; Sprague JE
    J Emerg Med; 2014 May; 46(5):632-42. PubMed ID: 24565885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Awash in a sea of 'bath salts': implications for biomedical research and public health.
    Baumann MH
    Addiction; 2014 Oct; 109(10):1577-9. PubMed ID: 24984975
    [No Abstract]   [Full Text] [Related]  

  • 5. Bath salts and synthetic cathinones: an emerging designer drug phenomenon.
    German CL; Fleckenstein AE; Hanson GR
    Life Sci; 2014 Feb; 97(1):2-8. PubMed ID: 23911668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Explosion of a New Designer Drug, Flakka: Implications for Practice.
    J Addict Nurs; 2018; 29(4):E16-E17. PubMed ID: 30507827
    [No Abstract]   [Full Text] [Related]  

  • 7. The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis.
    Abbott R; Smith DE
    J Psychoactive Drugs; 2015; 47(5):368-71. PubMed ID: 26579784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden cardiac death associated with methylone use.
    Carbone PN; Carbone DL; Carstairs SD; Luzi SA
    Am J Forensic Med Pathol; 2013 Mar; 34(1):26-8. PubMed ID: 23403480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder?
    Unterwald EM; Rawls SM
    J Pharmacol Exp Ther; 2023 Jun; 385(3):159-161. PubMed ID: 37197988
    [No Abstract]   [Full Text] [Related]  

  • 11. 'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.
    Smith CD; Robert S
    Clin Med (Lond); 2014 Aug; 14(4):409-15. PubMed ID: 25099844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary.
    Szily E; Bitter I
    Neuropsychopharmacol Hung; 2013 Dec; 15(4):223-31. PubMed ID: 24380963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Not for human consumption": a review of emerging designer drugs.
    Musselman ME; Hampton JP
    Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulant and Designer Drug Use: Primary Care Management.
    Klega AE; Keehbauch JT
    Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mephedrone related fatalities: a review.
    Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3777-90. PubMed ID: 26502870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel psychoactive substances: a novel clinical challenge.
    Smith CD; Williams M; Shaikh M
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23964049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DARK Classics in Chemical Neuroscience: α-Pyrrolidinovalerophenone ("Flakka").
    Kolesnikova TO; Khatsko SL; Demin KA; Shevyrin VA; Kalueff AV
    ACS Chem Neurosci; 2019 Jan; 10(1):168-174. PubMed ID: 30384587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging trends in the abuse of designer drugs and their catastrophic health effects: update on chemistry, pharmacology, toxicology and addiction potential.
    Rapaka RS; Purohit V; Schnur P; Rutter J
    Life Sci; 2014 Feb; 97(1):1. PubMed ID: 24529194
    [No Abstract]   [Full Text] [Related]  

  • 20. New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs.
    Helander A; Bäckberg M
    Clin Toxicol (Phila); 2017 Jan; 55(1):1-3. PubMed ID: 27549399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.